Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

KPV

Lys-Pro-Val, α-MSH (11-13)

Quick Stats
Studies 104
Trials 57
Score 2
2005 pubmed

Three-dimensional structure of the alpha-MSH-derived candidacidal peptide [Ac-CKPV]2.

Catania. A A; Grieco. P P; Randazzo. A A; Novellino. E E; Gatti. S S; Rossi. C C; Colombo. G G; Lipton. J M JM

Key Findings

  • The dimeric peptide [Ac-CKPV]2 shows strong candidacidal activity in vitro
  • It is effective against azole‑resistant Candida species
  • NMR and modeling reveal an extended backbone with a beta‑turn‑like structure

Practical Outcomes

  • The study points to a promising new antifungal candidate, but it’s still early‑stage research. Biohackers can note the potential of KPV‑based compounds for fungal issues, yet there’s no guidance on safe human use or dosing yet.

Summary

Scientists made a double‑linked version of a tiny peptide called KPV, naming it [Ac-CKV]2, and found it can kill Candida fungi, even strains that resist common antifungal drugs. Their lab work shows the molecule’s shape is stretched out with a small bend, which may help its killing power. However, they only tested it in the lab and didn’t give any dosing or safety info for people.

Abstract

Previous research has shown that the immunomodulatory peptide alpha-melanocyte-stimulating hormone (alpha-MSH) and its carboxy-terminal tripeptide KPV (Lys-Pro-Val alpha-MSH11-13) have antimicrobial influences. By inserting a Cys-Cys linker between two units of KPV, we designed the dimer [Ac-CKPV]2 that showed excellent candidacidal effects in pilot tests and was the subject of further investigations. [Ac-CKPV]2 was active against azole-resistant Candida spp. Therefore, the molecule appeared a promising candidate for therapy of fungal infections and was the subject of a structural study. 1H-NMR and restrained mechanic and dynamic calculations suggest that the peptide adopts an extended backbone structure with a beta-turn-like structure. These results open a pathway to development of additional novel compounds that have candidacidal effects potentially useful against clinical infections.

Study Information

Provider

pubmed

Year

2005

DOI

10.1111/j.1399-3011.2005.00265.x